European Journal of Dermatology
MENUParadoxical ulcerative colitis during treatment with secukinumab for psoriasis Volume 29, issue 4, July-August 2019
Figures
1 Department of Dermatology,
2 Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
- DOI : 10.1684/ejd.2018.3391
- Page(s) : 444-5
- Published in: 2019
Biologics may induce organ-specific and systemic autoimmune diseases as adverse events [1, 2]. Isolated cases of paradoxical ulcerative colitis (PUC) due to anti-tumour necrosis factor-alpha (TNFα) inhibitors, such as adalimumab, have been described [2]. We herein report PUC in a patient with psoriasis during treatment with secukinumab, an interleukin-17A (IL-17A) inhibitor.In October 2014, a 41-year-old woman was referred to us with a 27-year history of gradually progressive, generalized, asymptomatic [...]